Search company, investor...
Gelesis company logo

Gelesis

gelesis.com

Founded Year

2006

Stage

Reverse Merger | IPO

Total Raised

$200.48M

About Gelesis

Gelesis is a biotechnology company that develops a novel hydrogel platform technology to treat obesity and develops therapies for other chronic diseases related to the gastrointestinal (GI) tract.

Headquarters Location

501 Boylston Street Suite 6102

Boston, Massachusetts, 02116,

United States

617-391-9000

Missing: Gelesis's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Gelesis's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Research containing Gelesis

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Gelesis in 2 CB Insights research briefs, most recently on Mar 12, 2020.

Expert Collections containing Gelesis

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Gelesis is included in 2 Expert Collections, including Medical Devices.

M

Medical Devices

11,875 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health IT

7,901 items

Gelesis Patents

Gelesis has filed 1 patent.

The 3 most popular patent topics include:

  • Polymers
  • Polymer chemistry
  • Dosage forms
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/10/2018

1/11/2022

Diabetes, Obesity, Nutrition, Diets, Dietary supplements

Grant

Application Date

12/10/2018

Grant Date

1/11/2022

Title

Related Topics

Diabetes, Obesity, Nutrition, Diets, Dietary supplements

Status

Grant

Latest Gelesis News

Gelesis receives NYSE non-compliance letter for market cap and stockholders' equity

Nov 21, 2022

NYSE notified Gelesis (NYSE: GLS ) that its total market capitalization and stockholders' equity are below its compliance criteria. A company would be considered below criteria by the NYSE if its total market capitalization is less than $50M over a 30- trading day period and its stockholders' equity is less than $50M. The company is required to respond within 45 days of the Letter with a business plan that demonstrates compliance with the continued listing standard within 18 months of receipt of the letter. The letter has no immediate impact on the listing of the common stock, which will continue to trade on the NYSE under the symbol “GLS,” but will have an added designation of “.BC” to indicate that the company is not currently in compliance with NYSE continued listing standards. The company intends to cure deficiency and return to compliance with NYSE listing standard. Recommended For You

Gelesis Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Gelesis Rank

Gelesis Frequently Asked Questions (FAQ)

  • When was Gelesis founded?

    Gelesis was founded in 2006.

  • Where is Gelesis's headquarters?

    Gelesis's headquarters is located at 501 Boylston Street, Boston.

  • What is Gelesis's latest funding round?

    Gelesis's latest funding round is Reverse Merger.

  • How much did Gelesis raise?

    Gelesis raised a total of $200.48M.

  • Who are the investors of Gelesis?

    Investors of Gelesis include Capstar Special Purpose Acquisition, Paycheck Protection Program, European Regional Development Fund, Vitruvian Partners, Invesco Perpetual and 7 more.

  • Who are Gelesis's competitors?

    Competitors of Gelesis include Larimar Therapeutics, Orexigen Therapeutics, Probiodrug, VLST Corporation, Esperion Therapeutics and 13 more.

Compare Gelesis to Competitors

H
Halsa Pharmaceuticals

Halsa Pharmaceuticals is a biotechnology company developing therapeutics for the treatment of obesity, diabetes, cachexia and other metabolic diseases.

Celtaxsys Logo
Celtaxsys

Celtaxsys is a clinical-stage pharmaceutical development company focused on advancing novel foundational therapies to treat inflammation in rare, orphan designated diseases. The company's flagship investigational medicine, oral once daily acebilustat, is aimed at preserving lung function in cystic fibrosis (CF) by specifically modulating key aspects of a dysregulated (i.e. over-activated) immune response.

Protemix Logo
Protemix

Protemix is a biopharmaceutical company that discovers, develops and commercializes drug therapies for the prevention and treatment of cardiovascular disease, diabetes and other metabolic disorders and complications.

I
Innodia

Innodia Inc is a biotechnology company engaged in taking to the market drugs for the treatment of type 2 diabetes and related diseases and in generating value for its shareholders

moksha8 Logo
moksha8

Moksha8 is a specialty pharmaceutical company focused on licensing, marketing and distributing established therapeutics in Brazil and Mexico.

A
Anagen Therapeutics

Anagen Therapeutics is a biotechnology company focused on therapies for androgen and nuclear receptor-related diseases. Specific targets for its products under development include prostate disease, cardiovascular disease, neurodegenerative disease and skin disease.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.